Debt to Equity Ratio Chart

View Debt to Equity Ratio for SBFM.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Debt to Equity Ratio Chart
Start Trial

Historical Debt to Equity Ratio Data

View and export this data back to 2010. Start Trial.
Date Value
June 30, 2026 0.0246
March 31, 2026 0.0346
December 31, 2025 0.0353
September 30, 2025 0.0353
June 30, 2025 0.0362
March 31, 2025 0.0412
December 31, 2024 0.0405
September 30, 2024 0.0222
June 30, 2024 0.0246
March 31, 2024 0.0247
December 31, 2023 0.031
September 30, 2023 0.0307
June 30, 2023 0.0311
March 31, 2023 0.0378
December 31, 2022 0.0354
September 30, 2022 0.00
June 30, 2022 0.00
March 31, 2022 0.00
December 31, 2021 8.975
September 30, 2021 -3.011
June 30, 2021 -2.897
March 31, 2021 -2.529
December 31, 2020 -2.004
September 30, 2020 -1.831
June 30, 2020 -1.041
Date Value
March 31, 2020 -0.9056
December 31, 2019 -0.9731
September 30, 2019 -1.012
June 30, 2019 -0.9541
March 31, 2019 -5.853
December 31, 2018 -11.88
September 30, 2018 20.37
June 30, 2018 -4.611
March 31, 2018 -2.732
December 31, 2017 -1.399
September 30, 2017 -1.672
June 30, 2017 -0.6563
March 31, 2017 -0.9782
December 31, 2016 -1.130
September 30, 2016 0.7719
June 30, 2016 -2.114
March 31, 2016 -3.108
December 31, 2015 -1.911
September 30, 2015 -1.257
June 30, 2015 -1.472
March 31, 2015 -1.358
December 31, 2014 -1.239
September 30, 2014 -1.433
June 30, 2014 -0.8353
March 31, 2014 -1.170

Debt to Equity Ratio Definition

The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.

Read full definition.

Debt to Equity Ratio Range, Past 5 Years

View Debt to Equity Ratio Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Debt to Equity Ratio Benchmarks

View Debt to Equity Ratio Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 0.0565
Alnylam Pharmaceuticals, Inc. 2.206
Anika Therapeutics, Inc. 0.1839
Savara, Inc. 0.2117
Vericel Corp. 0.2556